1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Mitochondrial Diseases - Pipeline Review, H1 2014

Mitochondrial Diseases - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 50 pages

Mitochondrial Diseases - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Mitochondrial Diseases - Pipeline Review, H1 2014’, provides an overview of the Mitochondrial Diseases’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mitochondrial Diseases, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mitochondrial Diseases and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mitochondrial Diseases
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mitochondrial Diseases and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mitochondrial Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mitochondrial Diseases pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mitochondrial Diseases
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mitochondrial Diseases pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Mitochondrial Diseases - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mitochondrial Diseases Overview 6
Therapeutics Development 7
Pipeline Products for Mitochondrial Diseases - Overview 7
Pipeline Products for Mitochondrial Diseases - Comparative Analysis 8
Mitochondrial Diseases - Therapeutics under Development by Companies 9
Mitochondrial Diseases - Therapeutics under Investigation by Universities/Institutes 11
Mitochondrial Diseases - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Mitochondrial Diseases - Products under Development by Companies 14
Mitochondrial Diseases - Products under Investigation by Universities/Institutes 15
Mitochondrial Diseases - Companies Involved in Therapeutics Development 16
NeuroVive Pharmaceutical AB 16
Edison Pharmaceuticals, Inc. 17
ElexoPharm GmbH 18
Mitochondrial Diseases - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
vatiquinone - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
OT-15 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
MTP-131 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
NVP-015 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Alkylaminoquinone Based Multifunctional Radical Quenchers - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Eurostars Program - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Drug for Mitochondrial Diseases - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Drugs Targeting Cellular Energy Metabolism - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Small Molecules for Mitochondrial Diseases - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Mitochondrial Diseases - Recent Pipeline Updates 39
Mitochondrial Diseases - Dormant Projects 46
Mitochondrial Diseases - Discontinued Products 47
Mitochondrial Diseases - Product Development Milestones 48
Featured News and Press Releases 48
Mar 18, 2013: St George's University Of London Receives £3.3m MRC Grant For Developing New Treatment For Rare Metabolic Disorder 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables

Number of Products under Development for Mitochondrial Diseases, H1 2014 7
Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Mitochondrial Diseases - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 16
Mitochondrial Diseases - Pipeline by Edison Pharmaceuticals, Inc., H1 2014 17
Mitochondrial Diseases - Pipeline by ElexoPharm GmbH, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Mitochondrial Diseases Therapeutics - Recent Pipeline Updates, H1 2014 39
Mitochondrial Diseases - Dormant Projects, H1 2014 46
Mitochondrial Diseases - Discontinued Products, H1 2014 47

List of Figures

Number of Products under Development for Mitochondrial Diseases, H1 2014 7
Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Mucopolysaccharidosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.